ArticleAsian Pacific journal of cancer prevention : APJCP2024
Predicting HER2 Status Associated with Breast Cancer Aggressiveness Using Four Machine Learning Models.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic value and immune infiltration of novel markers TNRC6C/AMPD1 in pancreatic cancer microenvironment.Biochemistry and biophysics reports · 2025Article
- Multidimensional analysis reveals gene expression, cell interactions, and signaling networks in glioma and Alzheimer's disease.Discover oncology · 2025Article
- Novel deep learning-based prediction of HER2 expression in breast cancer using multimodal MRI, nomogram, and decision curve analysis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBreast cancer (BC) is a heterogeneous disease with various biological and clinical subtypes. HER2 status (human epidermal growth factor receptor 2) is a crucial biomarker, associated with aggressive tumor behavior and poor prognosis. Advanced algorithmic models can aid in predicting cancer growth and metastasis, serving as valuable clinical tools for classification and treatment. Effective treatment strategies in oncology rely on accurate decision-making and early identification of factors associated with positive outcomes. Breast cancer (BC) presents challenges in understanding its contributing factors and establishing precise diagnostic methods. Our research introduces a novel method utilizing machine learning (ML) techniques to explore the relationship between various clinical and molecular variables focusing on predicting the status of the human epidermal growth factor receptor 2 (HER2), a key aggressiveness biomarker in BC. This objective aligns with leveraging artificial intelligence (AI) to support decision-making and address diagnostic considerations during treatment.
methodsFour ML models, namely logistic regression, random forest, LightGBM, and CatBoost, were implemented and evaluated using Python. The dataset was compiled by extracting medical records of BC patients, covering the period from 2018 to 2020. The model's predictive performance was evaluated using accuracy, precision, recall, and F1-score as performance metrics.
resultThe models achieved varying accuracies between 86.36 and 95.45%. The logistic regression model achieved an accuracy of 90.90% while the random forest and LightGBM models achieved an accuracy of 86.36%. The CatBoost model outperformed others with a greater accuracy of 95.45%, indicating its superior predictive capabilities for HER2 status. The ML models demonstrated potential in predicting HER2 status, enabling early detection and facilitating personalized treatment strategies.
conclusionOur findings emphasize the significance of AI and ML techniques in improving BC outcomes and guiding decision-making. Further research is required to explore the broader applications of ML in predicting comprehensive BC outcomes in diverse healthcare settings and among heterogeneous populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.